Exact Sciences (NASDAQ:EXAS) PT Raised to $50.00 at Piper Sandler

Exact Sciences (NASDAQ:EXASGet Rating) had its target price hoisted by equities researchers at Piper Sandler from $40.00 to $50.00 in a report released on Monday, The Fly reports. The firm presently has a “neutral” rating on the medical research company’s stock. Piper Sandler’s price target would suggest a potential upside of 12.92% from the company’s current price.

EXAS has been the topic of a number of other research reports. Benchmark decreased their target price on shares of Exact Sciences to $54.00 in a research report on Tuesday, August 9th. Cowen cut their price target on shares of Exact Sciences from $83.00 to $67.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 3rd. Citigroup cut their target price on shares of Exact Sciences from $50.00 to $35.00 in a research note on Friday, November 4th. Robert W. Baird decreased their price objective on Exact Sciences from $75.00 to $60.00 in a report on Friday, November 4th. Finally, BTIG Research cut their price objective on Exact Sciences from $70.00 to $65.00 and set a “buy” rating for the company in a research report on Monday, November 7th. Five investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, Exact Sciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $64.86.

Exact Sciences Trading Down 1.2 %

NASDAQ EXAS opened at $44.28 on Monday. The firm’s 50-day moving average is $36.06 and its two-hundred day moving average is $41.83. Exact Sciences has a 12 month low of $29.27 and a 12 month high of $92.75. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.47 and a quick ratio of 2.20. The stock has a market capitalization of $7.87 billion, a P/E ratio of -10.80 and a beta of 1.31.

Insiders Place Their Bets

In other Exact Sciences news, insider Everett Cunningham sold 16,872 shares of the business’s stock in a transaction on Wednesday, October 12th. The stock was sold at an average price of $31.37, for a total transaction of $529,274.64. Following the completion of the transaction, the insider now owns 18,654 shares in the company, valued at approximately $585,175.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Exact Sciences

Institutional investors and hedge funds have recently modified their holdings of the stock. Steward Partners Investment Advisory LLC raised its position in shares of Exact Sciences by 44.4% during the second quarter. Steward Partners Investment Advisory LLC now owns 667 shares of the medical research company’s stock worth $26,000 after purchasing an additional 205 shares during the period. Ellevest Inc. raised its position in Exact Sciences by 103.6% during the second quarter. Ellevest Inc. now owns 682 shares of the medical research company’s stock valued at $27,000 after buying an additional 347 shares during the period. Signaturefd LLC raised its position in Exact Sciences by 45.7% during the third quarter. Signaturefd LLC now owns 957 shares of the medical research company’s stock valued at $31,000 after buying an additional 300 shares during the period. Householder Group Estate & Retirement Specialist LLC acquired a new position in Exact Sciences during the third quarter valued at $33,000. Finally, Capital Advisory Group Advisory Services LLC purchased a new position in Exact Sciences in the first quarter valued at about $37,000. 90.95% of the stock is owned by institutional investors and hedge funds.

About Exact Sciences

(Get Rating)

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services.

Featured Articles

The Fly logo

Analyst Recommendations for Exact Sciences (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.